Health Technology, Digital Healthcare
Montage Health | September 22, 2023
Montage Health Connected Care has launched an advanced service to enhance the quality and accessibility of healthcare for patients. This home-based patient monitoring service, supported by Cadence, is designed to offer proactive healthcare to individuals managing chronic medical conditions.
Dr. Mark Carvalho, Chief Executive Officer of Montage Medical Group, explained that the program lessens the need for emergency department visits by extending care directly to patients' homes. He emphasized that this approach offers mutual advantages for patients and healthcare providers.
Patients can gain access to an expanded care team from the comfort of their homes. At the same time, he added that clinicians will benefit from improved insights into disease progression and receive support from a nurse-practitioner-led care team, ultimately enhancing patient safety.
Montage Health's advanced remote care initiative represents a significant progression in its dedication to providing exceptional, personalized, value-based healthcare tailored to individual needs and objectives.
This program combines cutting-edge remote monitoring technology with a clinical care team under the direction of nurse practitioners to enable real-time collection, analysis, and response to patients' vital signs. It will support patients with medication management, laboratory assessments, and coaching to ensure outstanding healthcare and promote optimal well-being.
The process involves the daily use of smart devices for remote vital sign monitoring and remote care telephone consultations involving a diverse healthcare team.
Chris Altchek, CEO and Founder of Cadence said,
Montage Health exemplifies best-in-class preventative, restorative, and coordinated care with their strong track record of innovative programs and collaborative partnerships.
[Source – Business Wire]
Medicare beneficiaries will gain access to this offering at Montage Medical Group locations, resulting in reduced healthcare costs. This will also empower healthcare professionals to provide patients with better, more effective care.
About Montage Health
Montage Health is a local non-profit organization that delivers exceptional healthcare and promotes optimal health. The company strives to provide coordinated care that meets individual needs through its subsidiaries and partnerships with healthcare providers and community organizations. Its entities include Community Hospital of the Monterey Peninsula, Montage Medical Group, Montage Health Foundation, Montage Wellness Center, Aspire Health, and MoGo Urgent Care.
Cadence is a healthcare technology firm that assists the most patient-focused healthcare systems in consistently delivering proactive healthcare. The company's remote patient intervention solution blends technology and clinical expertise to deliver a tailored and precise standard of care that extends beyond the hospital's physical boundaries.
ClosedLoop | September 20, 2023
ClosedLoop, a prominent healthcare data science platform, has formally introduced two novel data science solutions.
These solutions, namely, ACO-Predict and Evaluate, are crafted to assist healthcare organizations in the comprehensive analysis, assessment, ongoing surveillance, and enhancement of their programs, with the objectives of minimizing adverse events, enhancing health outcomes, and curtailing expenditures.
ClosedLoop's offering, ACO-Predict, marks the healthcare sector's inaugural no-cost AI-powered solution for population health risk stratification. It harnesses the same algorithms that propelled ClosedLoop to garner fame in the 2021 CMS AI Challenge and earned the Best in KLAS Healthcare AI ranking for 2022 and 2023. When integrated with the updated Beneficiary Claims Data API data feeds from the Centers for Medicare and Medicaid Services, the product furnishes Medicare Accountable Care Organizations with a turnkey risk stratification tool for Complex Care Management programs, all free of charge.
Meanwhile, the company's second product, ClosedLoop Evaluate, is a SaaS solution designed to evaluate and continuously monitor the efficacy of intricate population health initiatives over extended durations. Quantifying the impact and ROI of Population Health programs has presented significant challenges. Organizations often need to resort to imprecise pre- and post-assessments or enlist costly consulting firms for one-off outcome research studies to understand the actual effects of their programs.
ClosedLoop’s solutions aim to improve healthcare organizations' outcomes and offer essential patient support.
Jennifer Zbell, VP of Clinical Analytics at Healthfirst, stated,
ClosedLoop provided the quantitative evidence we needed to increase investment in successful programs." She added, "Evaluate gives us the confidence to examine our programs across the board so we can better see what's working, when it's working, and who it's working for.
[Source – Business Wire]
ClosedLoop Evaluate represents a pioneering industry solution that not only supplants these studies with software-driven evaluations but also facilitates the ongoing assessment of program impact amid evolving programs and populations.
Andrew Eye, Co-Founder and CEO of ClosedLoop concluded that success in value-based care hinges on two key aspects: accurate prediction and effective intervention. ACO-Predict delivers AI-powered prediction capabilities to all medicare patients nationwide at no cost, ensuring access to necessary assistance regardless of location or ACO resources.
ClosedLoop is a dedicated data science platform tailored to the healthcare sector, simplifying the integration of AI technology to enhance outcomes and curtail expenses. Uniquely designed for the healthcare domain, the company merges an intuitive, all-encompassing ML platform with an extensive repository of healthcare-specific functionalities and model templates. Customers leverage ClosedLoop's Explainable AI capabilities to facilitate clinical excellence, streamline operational processes, navigate value-based contracts, and bolster revenue generation in the healthcare industry.
ShiftKey | September 15, 2023
ShiftKey, a leading technological enterprise at the forefront of reshaping the future of workforce engagement, has officially announced its expansion into acute healthcare facilities.
ShiftKey's technology, data resources, and talent marketplace are set to be accessible to acute care facilities in Kansas, Missouri, Tennessee, and Texas. This expansion addresses workforce-related challenges and enhances patients' access to top-tier healthcare services. Furthermore, the technology has already undergone beta testing at acute care facilities in Alabama, Louisiana, Nebraska, New Mexico, South Carolina, and West Virginia.
CEO of ShiftKey, Mike Vitek, characterized the company's foray into the acute care sector as a pivotal step in its platform and business development. He emphasized the organization's vantage point on healthcare staffing challenges and expressed optimism regarding the potential alleviation of strain on acute care facilities and healthcare professionals.
Meanwhile, Brandon Tappan, Chief Revenue Officer at ShiftKey, added that the escalating workforce challenges confronting healthcare facilities have become an annual trend. The departure of nurses from acute care facilities in large numbers underscores the imperative for a novel approach to address staffing needs within institutions serving vulnerable populations. Integrating ShiftKey's technology into acute care facilities represents establishing an independent healthcare staffing solution. This initiative aims to reinvigorate and safeguard this vital industry by enabling individuals to rejoin the workforce on their terms.
ShiftKey is a technological enterprise dedicated to transforming workforce access and integrity. Employing data and a marketplace model, the company facilitates connections between independent licensed professionals and facilities with workforce requirements. It is pivotal in advancing empowered labor, stability, and solutions for professionals, institutions, and beneficiaries. With a platform encompassing 10,000 healthcare facilities and myriad independently licensed professionals, ShiftKey is one of the foremost leaders in strategic workforce solutions, catalyzing a more sustainable, inclusive, and prosperous workforce economy for the years ahead.
Xenex | September 11, 2023
United States Food and Drug Administration (USFDA) has issued a De Novo authorization to Xenex Disinfection Services, Inc. (Xenex) for its LightStrikeTM+ device, an advanced high-intensity, broad-spectrum ultraviolet (UV) light robot.
The LightStrike+ devices are designed for microbial reduction on non-critical medical device surfaces in healthcare environments, following manual cleaning and disinfection practices. They are authorized for use in various healthcare settings, including unoccupied operating rooms and hospital rooms. These devices have an impressive track record, with over 1,200 healthcare facilities worldwide employing LightStrike robots for over 37 million cycles.
The new LightStrike+ device, capable of microbial reduction in as little as 2 minutes, represents the culmination of over a decade of knowledge accumulation from healthcare facilities' best practices, supported by 45 peer-reviewed studies demonstrating its safety and effectiveness, a portfolio of 193 patents, and unparalleled technical and epidemiological expertise.
Dr. Mark 'Tuck' Stibich, Xenex's Founder and Chief Scientific Officer, emphasized the long-standing collaboration with healthcare partners spanning more than a decade to enhance patient safety and public health.
As an infectious diseases epidemiologist, Dr. Stibich expressed concern about antibiotic resistance within hospital environments and the potential for FDA authorization to facilitate the broader adoption of the LightStrike+ tool in combating pathogens.
Perilous pathogens persist on surfaces within healthcare facilities, notwithstanding diligent manual cleaning endeavors. The LightStrike+ robot employs a xenon lamp to generate high-intensity pulsed UV light, which effectively diminishes the presence of these pathogens on surfaces and plays a pivotal role in interrupting the transmission chain from one patient or healthcare worker to another. Xenex's FDA authorization is substantiated by comprehensive testing conducted on more than 10,000 samples of vegetative bacteria and Clostridiodes difficile (C. diff) spores.
This authorization establishes a novel medical device product classification, with the LightStrike+ robot being its inaugural and sole product. It is a landmark in the FDA's regulatory framework for UV robots designed to diminish pathogens on non-porous, frequently touched surfaces within healthcare settings.
Furthermore, Xenex's Chief Executive Officer, Morris Miller, acknowledged the challenges hospitals face when evaluating UV technologies, citing the prevalence of unverified and exaggerated claims by some manufacturers. He underscored the significance of FDA authorization in instilling confidence among hospital decision-makers, assuring them of the accuracy and validation of Xenex's claims regarding the LightStrike+ device.
Numerous world-renowned hospitals, such as HonorHealth, Mayo Clinic, MD Anderson Cancer Center, Ochsner Health System, Stanford Health Care, and Texas Health Resources, have integrated LightStrike robots into their comprehensive disinfection strategies.
Xenex is a global leader in pioneering strategies and solutions grounded in UV technology. Its fundamental mission revolves around enabling its partners to safeguard lives and reduce human suffering by eliminating the dangerous microorganisms that cause infections. The company benefits from substantial support from renowned investors, including EW Healthcare Partners, Piper Sandler, Malin Corporation, Battery Ventures, Targeted Technology Fund II, Tectonic Ventures, and RK Ventures.